Pal SK - Search Results

1

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.

Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, Adeniran A, Narayan V, Bjarnason GA, Vaishampayan U, Alva A, Zhang T, Cole S, Plets M, Wright J, Lara PN Jr. Pal SK, et al. Lancet. 2021 Feb 20;397(10275):695-703. doi: 10.1016/S0140-6736(21)00152-5. Epub 2021 Feb 13. Lancet. 2021. PMID: 33592176 Free PMC article. Clinical Trial.

2

Targeted therapies for renal cell carcinoma: understanding their impact on survival.

Pal SK, Figlin RA. Pal SK, et al. Target Oncol. 2010 Jun;5(2):131-8. doi: 10.1007/s11523-010-0145-6. Epub 2010 Jul 15. Target Oncol. 2010. PMID: 20632214 Review.

3

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma.

Pal SK, Figlin RA. Pal SK, et al. Target Oncol. 2011 Mar;6(1):5-16. doi: 10.1007/s11523-011-0172-y. Epub 2011 Apr 12. Target Oncol. 2011. PMID: 21484496 Free PMC article. Review.

4

Systemic therapies for metastatic renal cell carcinoma in older adults.

Pal SK, Vanderwalde A, Hurria A, Figlin RA. Pal SK, et al. Drugs Aging. 2011 Aug 1;28(8):635-49. doi: 10.2165/11592880-000000000-00000. Drugs Aging. 2011. PMID: 21812499 Free PMC article. Review.

5

Role of surgery for locally advanced and metastatic renal cell carcinoma.

Torrey R, Spiess PE, Pal SK, Josephson D. Torrey R, et al. Among authors: pal sk. J Natl Compr Canc Netw. 2011 Sep 1;9(9):985-93. doi: 10.6004/jnccn.2011.0083. J Natl Compr Canc Netw. 2011. PMID: 21917623 Review.

6

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C. Pal SK, et al. Urol Oncol. 2013 Nov;31(8):1826-31. doi: 10.1016/j.urolonc.2012.04.007. Epub 2012 May 17. Urol Oncol. 2013. PMID: 22608544 Free PMC article.

7

Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma.

Carmichael C, Lau C, Josephson DY, Pal SK. Carmichael C, et al. Among authors: pal sk. Clin Adv Hematol Oncol. 2012 May;10(5):307-14. Clin Adv Hematol Oncol. 2012. PMID: 22706540 Review.

8

Differentiating mTOR inhibitors in renal cell carcinoma.

Pal SK, Quinn DI. Pal SK, et al. Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Cancer Treat Rev. 2013. PMID: 23433636 Free PMC article. Review.

9

Sequential treatment strategies and combination therapy regimens in metastatic renal cell carcinoma.

Pal SK, Vogelzang NJ. Pal SK, et al. Clin Adv Hematol Oncol. 2013 Mar;11(3):146-55. Clin Adv Hematol Oncol. 2013. PMID: 23598982 Review.

10

A gap in disease-specific survival between younger and older adults with de novo metastatic renal cell carcinoma: results of a SEER database analysis.

Nelson RA, Vogelzang N, Pal SK. Nelson RA, et al. Among authors: pal sk. Clin Genitourin Cancer. 2013 Sep;11(3):303-10. doi: 10.1016/j.clgc.2013.04.011. Epub 2013 May 4. Clin Genitourin Cancer. 2013. PMID: 23647940 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,104 results

Search Page